There is a newer version of this record available.

Working paper Open Access

Ivermectin for Covid-19

Sparavigna, Amelia Carolina


Citation Style Language JSON Export

{
  "publisher": "Zenodo", 
  "DOI": "10.5281/zenodo.3911707", 
  "language": "eng", 
  "title": "Ivermectin for Covid-19", 
  "issued": {
    "date-parts": [
      [
        2020, 
        6, 
        28
      ]
    ]
  }, 
  "abstract": "<p>Discussion of scholar papers published until June 28, 2020,&nbsp; on Ivermectin, and of news that we can find about its use for Covid-19.&nbsp; A list of clinical trials is also given. For what concerns scholar papers, we report among them a preprint posted on 10 June in MedR&chi;iv,&nbsp; which concludes that Ivermectin was associated with lower mortality during treatment of Covid-19.&nbsp; From news, we consider in particular the case of Iquitos,&nbsp; capital city of the Loreto Region in Peru, where, by May 25, Covid-19 cases and deaths had dropped notably.&nbsp;</p>", 
  "author": [
    {
      "family": "Sparavigna, Amelia Carolina"
    }
  ], 
  "note": "Before reading this work, please consider that I am not a physician. I do not suggest the use of ivermectin. I am not touting this drug. This analysis of publications and news about ivermectin is made in the framework of a wider investigation about information concerning drugs used for Covid-19.", 
  "type": "article", 
  "id": "3911707"
}
3,929
1,349
views
downloads
All versions This version
Views 3,929656
Downloads 1,349377
Data volume 348.3 MB81.2 MB
Unique views 3,216564
Unique downloads 1,121342

Share

Cite as